Published in Haematologica on November 10, 2008
Translational control in cancer. Nat Rev Cancer (2010) 4.59
A critical role for the NFkB pathway in multiple myeloma. Oncotarget (2010) 1.15
Inhibitor of apoptosis proteins as therapeutic targets in multiple myeloma. Leukemia (2014) 0.88
XIAP is not required for human tumor cell survival in the absence of an exogenous death signal. BMC Cancer (2010) 0.88
Myxoma Virus Induces Ligand Independent Extrinsic Apoptosis in Human Myeloma Cells. Clin Lymphoma Myeloma Leuk (2015) 0.83
Rational combination treatment with histone deacetylase inhibitors and immunomodulatory drugs in multiple myeloma. Blood Cancer J (2015) 0.83
Biologic impact of proteasome inhibition in multiple myeloma cells--from the aspects of preclinical studies. Semin Hematol (2012) 0.82
The ubiquitin-proteasomal system is critical for multiple myeloma: implications in drug discovery. Am J Blood Res (2011) 0.79
Cap-Independent Translational Control of Carcinogenesis. Front Oncol (2016) 0.79
Smac mimetic LCL161 overcomes protective ER stress induced by obatoclax, synergistically causing cell death in multiple myeloma. Oncotarget (2016) 0.78
Discovery of selective small-molecule HDAC6 inhibitor for overcoming proteasome inhibitor resistance in multiple myeloma. Proc Natl Acad Sci U S A (2016) 0.75
A dominant-negative F-box deleted mutant of E3 ubiquitin ligase, β-TrCP1/FWD1, markedly reduces myeloma cell growth and survival in mice. Oncotarget (2015) 0.75
mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res (2006) 18.44
Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. Cell (2000) 11.90
Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J Clin Invest (2008) 10.74
Translational control in stress and apoptosis. Nat Rev Mol Cell Biol (2005) 8.91
IAP proteins: blocking the road to death's door. Nat Rev Mol Cell Biol (2002) 7.23
Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome. Blood (2007) 5.55
Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proc Natl Acad Sci U S A (2002) 4.33
A serine protease, HtrA2, is released from the mitochondria and interacts with XIAP, inducing cell death. Mol Cell (2001) 4.24
IAPs: what's in a name? Mol Cell (2008) 3.66
Cleavage of human inhibitor of apoptosis protein XIAP results in fragments with distinct specificities for caspases. EMBO J (1999) 3.51
Activation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications. Oncogene (2002) 2.66
The phenotype of normal, reactive and malignant plasma cells. Identification of "many and multiple myelomas" and of new targets for myeloma therapy. Haematologica (2006) 2.12
Identification of XAF1 as an antagonist of XIAP anti-Caspase activity. Nat Cell Biol (2001) 2.02
Multiple myeloma: a prototypic disease model for the characterization and therapeutic targeting of interactions between tumor cells and their local microenvironment. J Cell Biochem (2007) 1.65
Targeting mitochondrial factor Smac/DIABLO as therapy for multiple myeloma (MM). Blood (2006) 1.56
Loss of XIAP protein expression by RNAi and antisense approaches sensitizes cancer cells to functionally diverse chemotherapeutics. Oncogene (2004) 1.47
Regulation and targeting of antiapoptotic XIAP in acute myeloid leukemia. Leukemia (2003) 1.39
Regulation of expression by promoters versus internal ribosome entry site in the 5'-untranslated sequence of the human cyclin-dependent kinase inhibitor p27kip1. Nucleic Acids Res (2005) 1.24
IAP family protein expression correlates with poor outcome of multiple myeloma patients in association with chemotherapy-induced overexpression of multidrug resistance genes. Am J Hematol (2006) 1.18
Translational regulation of x-linked inhibitor of apoptosis protein by interleukin-6: a novel mechanism of tumor cell survival. Cancer Res (2004) 1.09
Significant impact of survivin on myeloma cell growth. Leukemia (2007) 1.08
Mcl-1L cleavage is involved in TRAIL-R1- and TRAIL-R2-mediated apoptosis induced by HGS-ETR1 and HGS-ETR2 human mAbs in myeloma cells. Blood (2006) 1.03
Targeting the IAP family of caspase inhibitors as an emerging therapeutic strategy. Hematology Am Soc Hematol Educ Program (2005) 1.03
The treatment of relapsed and refractory multiple myeloma. Hematology Am Soc Hematol Educ Program (2007) 1.02
Production of metalloproteinase-7 (matrilysin) by human myeloma cells and its potential involvement in metalloproteinase-2 activation. J Immunol (1999) 0.95
Genetic heterogeneity in multiple myeloma. Leukemia (2005) 0.91
Canonical nuclear factor kappaB pathway inhibition blocks myeloma cell growth and induces apoptosis in strong synergy with TRAIL. Clin Cancer Res (2007) 0.90
Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome. Blood (2007) 5.55
Antisense strategy shows that Mcl-1 rather than Bcl-2 or Bcl-x(L) is an essential survival protein of human myeloma cells. Blood (2002) 2.38
Noxa up-regulation and Mcl-1 cleavage are associated to apoptosis induction by bortezomib in multiple myeloma. Cancer Res (2007) 2.37
Patients with drug-free long-term graft function display increased numbers of peripheral B cells with a memory and inhibitory phenotype. Kidney Int (2010) 2.28
Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA--Italian Multiple Myeloma Network. J Clin Oncol (2007) 2.14
The phenotype of normal, reactive and malignant plasma cells. Identification of "many and multiple myelomas" and of new targets for myeloma therapy. Haematologica (2006) 2.12
Recurrent 14q32 translocations determine the prognosis of multiple myeloma, especially in patients receiving intensive chemotherapy. Blood (2002) 1.87
A high-risk signature for patients with multiple myeloma established from the molecular classification of human myeloma cell lines. Haematologica (2010) 1.80
Low vitamin D status, high bone turnover, and bone fractures in centenarians. J Clin Endocrinol Metab (2003) 1.79
The proteasome load versus capacity balance determines apoptotic sensitivity of multiple myeloma cells to proteasome inhibition. Blood (2009) 1.77
Multiple myeloma bone disease: Pathophysiology of osteoblast inhibition. Blood (2006) 1.77
Bortezomib as induction before autologous transplantation, followed by lenalidomide as consolidation-maintenance in untreated multiple myeloma patients. J Clin Oncol (2010) 1.76
The proteasome inhibitor bortezomib affects osteoblast differentiation in vitro and in vivo in multiple myeloma patients. Blood (2007) 1.75
Diabetes impairs hematopoietic stem cell mobilization by altering niche function. Sci Transl Med (2011) 1.75
Myeloma cells block RUNX2/CBFA1 activity in human bone marrow osteoblast progenitors and inhibit osteoblast formation and differentiation. Blood (2005) 1.59
Bortezomib induction, reduced-intensity transplantation, and lenalidomide consolidation-maintenance for myeloma: updated results. Blood (2013) 1.57
Pomalidomide, cyclophosphamide, and prednisone for relapsed/refractory multiple myeloma: a multicenter phase 1/2 open-label study. Blood (2013) 1.55
Human myeloma cells stimulate the receptor activator of nuclear factor-kappa B ligand (RANKL) in T lymphocytes: a potential role in multiple myeloma bone disease. Blood (2002) 1.47
Endothelial dysfunction and cardiovascular risk profile in long-term withdrawing alcoholics. J Hypertens (2007) 1.47
Translocation t(11;14)(q13;q32) is the hallmark of IgM, IgE, and nonsecretory multiple myeloma variants. Blood (2002) 1.42
Toll-like receptors: lessons to learn from normal and malignant human B cells. Blood (2008) 1.42
Dexamethasone-based regimens versus melphalan-prednisone for elderly multiple myeloma patients ineligible for high-dose therapy. Blood (2005) 1.35
IL-3 is a potential inhibitor of osteoblast differentiation in multiple myeloma. Blood (2005) 1.35
ABT-737 is highly effective against molecular subgroups of multiple myeloma. Blood (2011) 1.35
Pulmonary hypertension is frequent in hyperthyroidism and normalizes after therapy. Eur J Intern Med (2006) 1.32
Production of Wnt inhibitors by myeloma cells: potential effects on canonical Wnt pathway in the bone microenvironment. Cancer Res (2007) 1.18
Targeting MEK/MAPK signal transduction module potentiates ATO-induced apoptosis in multiple myeloma cells through multiple signaling pathways. Blood (2008) 1.16
CD221 (IGF-1R) is aberrantly expressed in multiple myeloma, in relation to disease severity. Haematologica (2005) 1.16
Melphalan-induced apoptosis in multiple myeloma cells is associated with a cleavage of Mcl-1 and Bim and a decrease in the Mcl-1/Bim complex. Oncogene (2005) 1.15
The imbalance between Bim and Mcl-1 expression controls the survival of human myeloma cells. Eur J Immunol (2004) 1.11
Lack of CD27 in myeloma delineates different presentation and outcome. Br J Haematol (2006) 1.10
Gene expression profiling of multiple myeloma reveals molecular portraits in relation to the pathogenesis of the disease. Blood (2003) 1.09
Interleukin-27 acts as multifunctional antitumor agent in multiple myeloma. Clin Cancer Res (2010) 1.09
Tandem autologous stem cell transplantation in high-risk de novo multiple myeloma: final results of the prospective and randomized IFM 99-04 protocol. Blood (2005) 1.09
Cell death via DR5, but not DR4, is regulated by p53 in myeloma cells. Cancer Res (2012) 1.08
Distinct transcriptional profiles characterize bone microenvironment mesenchymal cells rather than osteoblasts in relationship with multiple myeloma bone disease. Exp Hematol (2009) 1.06
Phenotypic characterization of the human myeloma cell growth fraction. Blood (2005) 1.04
CXCR3 and its binding chemokines in myeloma cells: expression of isoforms and potential relationships with myeloma cell proliferation and survival. Haematologica (2006) 1.03
New insight in the mechanism of osteoclast activation and formation in multiple myeloma: focus on the receptor activator of NF-kappaB ligand (RANKL). Exp Hematol (2004) 1.01
New insights in myeloma-induced osteolysis. Leuk Lymphoma (2003) 1.01
The p53 family protein p73 provides new insights into cancer chemosensitivity and targeting. Clin Cancer Res (2009) 1.01
Endogenous association of Bim BH3-only protein with Mcl-1, Bcl-xL and Bcl-2 on mitochondria in human B cells. Eur J Immunol (2005) 1.00
Prediction of metastatic relapse in node-positive breast cancer: establishment of a clinicogenomic model after FEC100 adjuvant regimen. Breast Cancer Res Treat (2007) 1.00
CC-chemokine ligand 20/macrophage inflammatory protein-3α and CC-chemokine receptor 6 are overexpressed in myeloma microenvironment related to osteolytic bone lesions. Cancer Res (2008) 0.99
Proangiogenic properties of human myeloma cells: production of angiopoietin-1 and its potential relationship to myeloma-induced angiogenesis. Blood (2003) 0.99
Light-chain only multiple myeloma is due to the absence of functional (productive) rearrangement of the IgH gene at the DNA level. Blood (2004) 0.98
IL-21 stimulates human myeloma cell growth through an autocrine IGF-1 loop. J Immunol (2008) 0.98
OPG/RANKL system imbalance in a case of hepatitis C-associated osteosclerosis: the pathogenetic key? Clin Rheumatol (2004) 0.97
The peripheral CD138+ population but not the CD138- population contains myeloma clonogenic cells in plasma cell leukaemia patients. Br J Haematol (2011) 0.97
14q32 Translocations discriminate IgM multiple myeloma from Waldenstrom's macroglobulinemia. Semin Oncol (2003) 0.97
c-Myc dependent expression of pro-apoptotic Bim renders HER2-overexpressing breast cancer cells dependent on anti-apoptotic Mcl-1. Mol Cancer (2011) 0.97
Reciprocal protection of Mcl-1 and Bim from ubiquitin-proteasome degradation. Biochem Biophys Res Commun (2007) 0.95
CD45neg but not CD45pos human myeloma cells are sensitive to the inhibition of IGF-1 signaling by a murine anti-IGF-1R monoclonal antibody, mAVE1642. J Immunol (2006) 0.95
The imbalance between Survivin and Bim mediates tumour growth and correlates with poor survival in patients with multiple myeloma. Br J Haematol (2009) 0.95
Clinical management of paroxysmal nocturnal hemoglobinuria in pregnancy: a case report and updated review. Obstet Gynecol Surv (2006) 0.95
Epithelial-to-mesenchymal transition induced by TGF-β1 is mediated by Blimp-1-dependent repression of BMP-5. Cancer Res (2012) 0.94
Myeloma cells and bone marrow osteoblast interactions: role in the development of osteolytic lesions in multiple myeloma. Leuk Lymphoma (2007) 0.94
TLR3 ligand induces NF-{kappa}B activation and various fates of multiple myeloma cells depending on IFN-{alpha} production. J Immunol (2009) 0.93
Elevated tumor necrosis factor-alpha suppresses TAZ expression and impairs osteogenic potential of Flk-1+ mesenchymal stem cells in patients with multiple myeloma. Stem Cells Dev (2007) 0.92
ADAM8 expression in invasive breast cancer promotes tumor dissemination and metastasis. EMBO Mol Med (2013) 0.92
Immunomodulatory drugs lenalidomide and pomalidomide inhibit multiple myeloma-induced osteoclast formation and the RANKL/OPG ratio in the myeloma microenvironment targeting the expression of adhesion molecules. Exp Hematol (2012) 0.92
Novel targeting of phospho-cMET overcomes drug resistance and induces antitumor activity in multiple myeloma. Clin Cancer Res (2013) 0.91
Prevalence and significance of hypoalbuminemia in an internal medicine department. Eur J Intern Med (2008) 0.90
Total soluble HLA class I and soluble HLA-G in multiple myeloma and monoclonal gammopathy of undetermined significance. Clin Cancer Res (2005) 0.90
Canonical nuclear factor kappaB pathway inhibition blocks myeloma cell growth and induces apoptosis in strong synergy with TRAIL. Clin Cancer Res (2007) 0.90
Advances in biology and therapy of multiple myeloma. Hematology Am Soc Hematol Educ Program (2003) 0.89
Osteogenic differentiation of mesenchymal stem cells in multiple myeloma: identification of potential therapeutic targets. Exp Hematol (2009) 0.88
The magnitude of Akt/phosphatidylinositol 3'-kinase proliferating signaling is related to CD45 expression in human myeloma cells. J Immunol (2004) 0.88
CD38 expression and secondary 17p deletion are important prognostic factors in chronic lymphocytic leukaemia. Br J Haematol (2002) 0.88
MDR1 polymorphism influences the outcome of multiple myeloma patients. Br J Haematol (2007) 0.87
A 38-gene expression signature to predict metastasis risk in node-positive breast cancer after systemic adjuvant chemotherapy: a genomic substudy of PACS01 clinical trial. Breast Cancer Res Treat (2008) 0.87
Angiogenic switch in multiple myeloma. Hematology (2005) 0.87
Osteoclasts support the survival of human plasma cells in vitro. Int Immunol (2008) 0.87
Serum CXCL10 levels and occurrence of thyroid dysfunction in patients treated with interferon-alpha therapy for hepatitis C virus-related hepatitis. Eur J Endocrinol (2007) 0.87
Crucial role of phosphatase CD45 in determining signaling and proliferation of human myeloma cells. Eur Cytokine Netw (2007) 0.85
Overexpression of HOXB7 and homeobox genes characterizes multiple myeloma patients lacking the major primary immunoglobulin heavy chain locus translocations. Am J Hematol (2011) 0.85
Serum vitamin D concentration and short-term mortality among geriatric inpatients in acute care settings. Adv Ther (2010) 0.85
Unraveling the contribution of ectoenzymes to myeloma life and survival in the bone marrow niche. Ann N Y Acad Sci (2014) 0.84
Red cell Hb oxidation of healthy subjects compared to breast cancer patients. Anticancer Res (2003) 0.84
γ-Secretase inhibition promotes cell death, Noxa upregulation, and sensitization to BH3 mimetic ABT-737 in human breast cancer cells. Breast Cancer Res (2012) 0.83
Bleomycin genotoxicity and amifostine (WR-2721) cell protection in normal leukocytes vs. K562 tumoral cells. Biochem Pharmacol (2002) 0.83
Critical role of the NOTCH ligand JAG2 in self-renewal of myeloma cells. Blood Cells Mol Dis (2012) 0.83
Is steroid therapy needed in the treatment of destructive thyrotoxicosis induced by alpha-interferon in chronic hepatitis C? Horm Res (2005) 0.83
Hemisynthesis of selected embelin analogs and investigation of their proapoptotic activity against cancer cells. Med Chem (2013) 0.83
Plasma beta-2 microglobulin as a marker of frailty in older adults: a pilot study. J Gerontol A Biol Sci Med Sci (2011) 0.83
Hematologic malignancies with extramedullary spread of disease. Case 1. Multiple myeloma with extramedullary involvement of the pleura and testes. J Clin Oncol (2003) 0.82
Acute antiarrhythmic effects of bi-level positive airway pressure ventilation in patients with acute respiratory failure caused by chronic obstructive pulmonary disease: a randomized clinical trial. Respiration (2004) 0.82